Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612229 | 0.88 | CTSS (0.48) | EPHX1CTSSCTSKGAABTK | |
| SCHEMBL3612235 | 0.88 | CTSS (0.48) | EPHX1CTSSCTSKGAABTK | |
| SCHEMBL3610835 | 0.87 | EPHX1 (0.43) | EPHX1CTSSCTSKGAACNR2 | |
| SCHEMBL3610831 | 0.87 | EPHX1 (0.43) | EPHX1CTSSCTSKGAACNR2 | |
| SCHEMBL3619406 | 0.78 | EPHX1 (0.43) | EPHX1CTSSCTSKGAABTK | |
| SCHEMBL3619402 | 0.78 | EPHX1 (0.43) | EPHX1CTSSCTSKGAABTK | |
| SCHEMBL5351400 | 0.77 | KMT2A (0.37) | EPHX1CTSSCTSKGAAKMT2A | |
| SCHEMBL17771895 | 0.77 | CTSK (0.37) | EPHX1CTSSCTSKGAACNR2 | |
| SCHEMBL3039514 | 0.75 | EPHX1 (0.41) | EPHX1CTSSCTSKGAABTK | |
| SCHEMBL5351874 | 0.75 | GAA (0.45) | EPHX1CTSKGAAHDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866422-B2 | Carbocyclic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2024-01-09 | — | — | US | disclosed |
| US-11267803-B2 | Carbocyclic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2022-03-08 | — | — | US | disclosed |
| US-20210347762-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210347762-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2021-11-11 | — | — | US | disclosed |
| US-11091465-B2 | — | — | 2021-08-17 | — | — | US | disclosed |
| US-11091465-B2 | — | — | 2021-08-17 | — | — | US | disclosed |
| US-20200385362-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2020-12-10 | — | — | US | disclosed |
| US-20200385362-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2020-12-10 | — | — | US | disclosed |
| US-20190202810-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190202810-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-07-04 | — | — | US | disclosed |
| EP-3472151-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | ORION OPTHALMOLOGY LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017222914-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | INCEPTION 4, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202810-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | HTRA1, ADCYAP1R1, HTRA2 | EPHX1 2203/4885CTSS 402/4885CTSK 983/4885 |
| US-11267803-B2 | Carbocyclic prolinamide derivatives | HTRA1, ADCYAP1R1, HTRA2 | EPHX1 2203/4885CTSS 402/4885CTSK 983/4885 |
| US-20200385362-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | HTRA1, ADCYAP1R1, HTRA2 | EPHX1 2203/4885CTSS 402/4885CTSK 983/4885 |
| US-11866422-B2 | Carbocyclic prolinamide derivatives | HTRA1, ADCYAP1R1, HTRA2 | EPHX1 2203/4885CTSS 402/4885CTSK 983/4885 |
| US-11091465-B2 | — | HTRA1, ALDH1A2, ADCYAP1R1 | EPHX1 1905/4885CTSS 341/4885CTSK 823/4885 |
| US-20210347762-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | HTRA1, ADCYAP1R1, HTRA2 | EPHX1 2203/4885CTSS 402/4885CTSK 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.